Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This Bitcoin-first microcap is using its balance sheet to accumulate BTC (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Rigel Pharmaceuticals Inc RIGL

Healthcare Biotechnology
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:RIGL)

Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition

PR Newswire December 7, 2025

Rigel to Present at the Piper Sandler 37th Annual Healthcare Conference

PR Newswire November 26, 2025

Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology

PR Newswire November 17, 2025

Rigel to Present at the Jefferies Global Healthcare Conference in London

PR Newswire November 12, 2025

Rigel Reports Third Quarter 2025 Financial Results and Provides Business Update

PR Newswire November 4, 2025

Rigel Announces One Oral and Four Poster Presentations at the 67th American Society of Hematology Annual Meeting and Exposition

PR Newswire November 3, 2025

Rigel Announces Conference Call and Webcast to Report Third Quarter 2025 Financial Results and Business Update

PR Newswire October 29, 2025

Rigel Announces First Patient Enrolled in the Dose Expansion Phase of its Phase 1b Study of R289 in Patients with Lower-Risk MDS

PR Newswire October 8, 2025

Rigel Pharmaceuticals, Inc. Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PR Newswire October 3, 2025
View More News ››

Opinion & Analysis (NDAQ:RIGL)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RIGL)

Rigel Pharmaceuticals (RIGL): A Promising Hematology and Onc

http://beyondspx.com/2024/07/31/rigel-pharmaceuticals-rigl-a-promising-hematology-and-oncology-player-poised-for-growth/
MikeTester - August 2, 2024

4 BIOTECH STOCKS FOR YOUR INVESTMENT WATCHLIST!

FSTX, RIGL, CRNX, KLDO,  Read More
AviseAnalytics - August 9, 2021

Rigel Pharmaceuticals Awarded US Patent

Stock is up in pre-market. News only on benzinga so far.  https://www.benzinga.com/news/21/03/20071260/rigel-pharmaceuticals-awarded...
BudFawks - March 9, 2021

going bankrupe

not good for them
Danalo - April 5, 2013

Type 1 Diabetes and R788

announced that its oral Syk kinase inhibitor, R788, may be a useful treatment for type 1 diabetes mellitus, according to research being...
mart33 - April 10, 2008

QP ending

Quiet Period ending Friday. Get in. Get out. Money!
rshle - December 21, 2000
View more Bullboard ››

Allied Critical Metals Inc.

Allied Critical Metals Inc.

Allied Critical Metals (ACM:CSE) is a Canadian-based mining company focused on the expansion and revitalization of its 100 ...
View More »

Podcasts